IP Library Granted Patent US 8,852,613
Granted Patent B2
US 8,852,613 · App. 13/869,574 · Granted Oct 7, 2014

One dose vaccination against

Inventors: William Charles Ohnesorge (Saint Joseph, MO); Isabelle Freiin von Richthofen (Charlottenlund, DK); Marika Christine Genzow (Wiesbaden, DE); Martina von Freyburg (Mainz, DE); Carola Kissel (Kansas City, MO); Luc-Etienne Fabry (Bingen, DE); Knut Elbers (Mittelbiberach, DE); Kathleen Kwan Young Park (St. Joseph, MO)
Assignee: Boehringer Ingelheim Vetmedica, Inc.
A61K39/0241A61K39/40C12R1/35C12N1/20A61K2039/552A61K2039/521
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,852,613
App. No.
13/869,574
Granted
Oct 7, 2014
Kind
B2
Abstract

The present invention provides a one phase, aqueous vaccine composition for immunizing an animal against infection by Mycoplasma hyopneumoniae , comprising: an immunizing amount of a Mycoplasma hyopneumoniae bacterin, an acrylic acid polymer in the concentration range between 0.8 and 1.2 mg/ml, and a pharmaceutically acceptable carrier, and substantially no oil. It is especially useful for immunizing a pig against infection by Mycoplasma hyopneumoniae for at least 20 weeks after a single administration, which effective immunity is reached within 4 weeks after vaccination.

Claims (11)

1. A method of preparing a one phase aqueous composition comprising a Mycoplasma hyopneumoniae bacterin, an acrylic acid polymer in a concentration range between 0.8 and 1.2 mg/ml, a pharmaceutically acceptable carrier, and substantially no oil;

comprising:

a. cultivating a M. hyopneumoniae whole cell culture such that the Mycoplasma hyopneumoniae bacterin has an antigen amount of at least 3 log 10 per ml;

b. inactivating the M. hyopneumoniae whole cell culture;

c. isolating an immunizing amount of a Mycoplasma hyopneumoniae bacterin;

d. admixing an acrylic acid polymer in the concentration range between 0.8 and 1.2 mg/ml; and

e. admixing a pharmaceutically acceptable carrier.

2. The method of claim 1 , wherein the M. hyopneumoniae whole cell culture is inactivated by a method selected from the group consisting of heat denaturation, shear force, and a chemical agent.

3. The method of claim 2 , wherein the chemical agent is selected from the group consisting of binary ethyleneimine (BEI) and formalin.

4. The method of claim 1 , wherein the one phase, aqueous composition consists essentially of no other ingredients.

5. The method of claim 1 , wherein said one phase, aqueous composition consists essentially of substantially pure formalin-inactivated whole cell Mycoplasma hyopneumoniae J (ATCC 25934) bacterin having an antigen amount between 5 log 10 and 8 log 10 per ml before inactivation; about 1 mg/ml carbomer; and up to 1 ml 0.85% (w/v) sodium chloride aqueous solution.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Jul 24, 2020
From: BOEHRINGER INGELHEIM VETMEDICA, INC.; BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
To: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
Reel/Frame 053310/0420 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2020
From: VON FREYBURG, MARTINA; ELBERS, KNUT; FABRY, LUC-ETIENNE; VON RICHTHOFEN, ISABELLE FREIIN; GENZOW, MARIKA; KISSEL, CAROLA; OHNESORGE, WILLIAM CHARLES; PARK, KATHLEEN
To: BOEHRINGER INGELHEIM VETMEDICA, INC.
Reel/Frame 053282/0228 →
Continuity (3)
Division 12423658 · Apr 14, 2009
Provisional Application 61046244 · Apr 18, 2008
Related Publication 20130230558A1 · Sep 5, 2013